Novel Vascular Graft
At MIMESIS we have developed a technology with the potential to address vascular problem for patients with diabetes and lower limb ischemia.
Our novel vascular graft, Blood Vessel Mimic, offers a novel solution for surgeons’ challenge to bypass the obstruction of peripheral blood vessels and restore the blood flow.
The use of Mimesis
Peripheral Artery Diseases (PAD) affects around 230 million adults worldwide and its most sever manifesation is Critical Limb Ischemia (CLTI) which is associated with a 20% risk of amputation within one year from the diagnosis.
Lower limb bypass grafting is the gold standard in surgical practice, yet an excess of around 3,000 amputations is necessary every year in UK.
How does Mimesis help?
The Mimesis Blood Vessel Mimc (BVM) is an innovative vascular graft at the stage of validation, that can be transplanted to treat pateinets with Peripheral Artery Diseases.
The BVM is a pre-cellularised graft with the potential to grow and remodel with the patient reducing the risk of failure and reintervention.
A goal of Mimesis is to provide a pre-cellularised graft that avoids the rejection from the patient’s immune system by accurate selection of haplotyped donor cells.
Mimesis: The Future of Medicine!
Help us shape the future of medicine by taking this very short survey. We are keen to hear from surgeons and clinicians.
Our Team
Dr Michele Carrabba
Entrepreneurial Lead
Prof Giovanni Biglino
Principal Scientific Advisor
Prof Massimo Caputo
Chair and Clinical Development
Olivia Champion
Technology Transfer Office
Contact Form
Want more information?
Enquire About Mimesis
Have a query about our developed technology to address the vascular problems for patients with diabetes and lower limb ischemia that risk amputations? Then please fill out the contact form and we will get back to you.